Phase i pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors

European Journal of Cancer

Volumn 49, Issue 5, 2013, Pages 989-998

  Simonelli, Matteo ^a   Zucali, Paolo A ^a   Lorenzi, Elena ^a   Rubino, Luca ^a   De Vincenzo, Fabio ^a   De Sanctis, Rita ^a   Perrino, Matteo ^a   Mancini, Luca ^a   Di Tommaso, Luca ^a   Rimassa, Lorenza ^a   Masci, Giovanna ^a   Zuradelli, Monica ^a   Suter, Matteo B ^a   Bertossi, Monica ^a   Fattuzzo, Giuseppe ^a   Giordano, Laura ^a   Roncalli, Massimo G ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Advanced refractory solid tumours; Lapatinib; Phase I; Sorafenib

Indexed keywords

LAPATINIB; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; BREAST TUMOR; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL TUMOR; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOPENIA; MALE; MESOTHELIOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE TUMOR; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; STOMACH TUMOR; STUDY DESIGN; THROMBOCYTOPENIA; THYMUS CANCER; TRANSITIONAL CELL CARCINOMA; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; QUINAZOLINES;

EID: 84874931018     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.10.016     Document Type: Article

References (33)

1. L. Gossage, and T. Eisen Targeting multiple kinase pathways: a change in paradigm Clin Cancer Res 16 2010 1973 1978
2. N.E. Hynes, and G. MacDonald ErbB receptors and signaling pathways in cancer Curr Opin Cell Biol 21 2009 177 184
3. R.S. Kerbel Tumor angiogenesis N Engl J Med 358 2008 2039 2049
4. A.K. Larsen, D. Ouaret, K. El Ouadrani, and A. Petitprez Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis Pharmacol Ther 131 2011 80 90
5. D.L. Wheeler, E.F. Dunn, and P.M. Harari Understanding resistance to EGFR inhibitors - impact on future treatment strategies Nat Rev Clin Oncol 7 2010 493 507
6. F. Ciardiello, R. Bianco, and V. Damiano Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clin Cancer Res 6 2000 3739 3747
7. P. Sini, L. Wyder, and C. Schnell The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade Clin Cancer Res 11 2005 4521 4532
8. L.B. Saltz, H.J. Lenz, and H.L. Kindler Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 2007 4557 4561
9. R.S. Herbst, D.H. Johnson, and E. Mininberg Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2005 2544 2555
10. J.R. Hecht, E. Mitchell, and T. Chidiac A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
11. V. Poindessous, D. Ouaret, and K. El Ouadrani EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies Clin Cancer Res 17 2011 6522 6530
12. D.W. Rusnak, K. Affleck, and S.G. Cockerill The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer Cancer Res 61 2001 7196 7203
13. C.E. Geyer, J. Forster, and D. Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743
14. S. Johnston, J. Pippen Jr, X. Pivot, M. Lichinitser, S. Sadeghi, and V. Dieras Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol 27 2009 5538 5546
15. C.H. Takimoto, and A. Awada Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials Cancer Chemother Pharmacol 61 2008 535 548
16. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
17. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
18. E. Martinelli, T. Troiani, F. Morgillo, G. Rodoligo, D. Vitagliano, and P. Morelli Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells Clin Cancer Res 15 2010 4990 5001
19. F. Morgillo, E. Martinelli, T. Troiani, M. Ordimura, F. De Vita, and F. Ciardiello Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors PLoS One 6 2011 e28841
20. I. Duran, S.J. Hotté, and H. Hirte Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors Clin Cancer Res 13 2007 4849 4857
21. S. Hsieh, T. Tobien, K. Koch, and J. Dunn Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development Rapid Commun Mass Spectrom 18 2004 285 292
22. D. Strumberg, H. Richly, and R.A. Hilger Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 10 2005 965 972
23. J. Rhee, S.W. Han, and Y. Chay High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer Breast Cancer Res treat 125 2011 107 114
24. H.H. Kong, V. Sibaud, M.L. Chanco Turner, T. Fojo, T.J. Hornyak, and C. Chevreau Sorafenib-induced eruptive melanocytic lesions Arch Dermatol 144 2008 820 822
25. M. Hipp, N. Hilf, S. Walter, D. Werth, K.M. Brauer, and M.P. Radsaki Sorafenib but not sunitinib affects function of dendritic cells and induction of primary immune responses Blood 111 2008 5610 5620
26. E600- associated senescence-like cell cycle arrest of human naevi Nature 436 2005 720 724
27. J.M. Llovet, C.E. Peña, and C.D. Lathia On behalf of the SHARP Investigators Study Group: plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma Clin Cancer Res 18 2012 2290 2300
28. H.J. Burstein, A.D. Elias, and H.S. Rugo Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 2008 1810 1816
29. J.S. Lind, A.M. Dingemans, and H.J. Groen A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer Clin Cancer Res 16 2010 3078 3087
30. Backlund DC, Goff LW, Chan E, et al. A phase II trial of sorafenib (S) and erlotinib (E) in unresectable pancreas cancer: preliminary results. Presented at the 2010 Gastrointestinal Cancer Symposium, 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 22-24, 2010 [abstr 264].
31. M. Prados, M. Gilbert, and J. Kuhn Phase I/II study of sorafenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02) J Clin Oncol 27 15s 2009 [Suppl.; abstr 2005]
32. R.J. Kelly, I. Petrini, A. Rajan, Y. Wang, and G. Giaccone Thymic malignancies: from clinical management to targeted therapies J Clin Oncol 29 2011 4820 4827
33. A. Prahallad, C. Sun, and S. Huang Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100 103